Dr. Shane Alun James Lloyd, MD, PhD

Dr. Lloyd practices at Newport Coast Radiation Oncology Medical Group, Inc in Irvine, California.

Dr. Lloyd's NPI, 1427443068, was assigned on March 31, 2015. Dr. Lloyd graduated from Penn State College of Medicine in 2015. Dr. Lloyd holds California license A146615.

Dr. Lloyd's primary practice is Newport Coast Radiation Oncology Medical Group, Inc, at 16105 Sand Canyon Ave, Irvine, CA 92618 in Orange County. The practice phone is (949) 764-5528.

Dr. Lloyd's primary practice is Newport Coast Radiation Oncology Medical Group, Inc in Irvine, California. Dr. Lloyd is also affiliated with UCI Health - Orange. The medical group on file is Newport Coast Radiation Oncology Medical Group. Dmand AI also links Dr. Lloyd to 1 more hospital and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lloyd practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Lloyd's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Lloyd is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Lloyd's licenses on file in 3 states: California, Utah and Connecticut.

Dmand AI lists anal cancer radiation, bone cancer radiation, brain cancer radiation, brain tumor radiation, breast cancer radiation, cancer radiation-upper GI, colorectal cancer radiation and head & neck cancer radiation among the conditions Dr. Lloyd treats.

CMS data shows 3,690 Medicare services from Dr. Lloyd across 15 procedure codes in 2024, for 263 Medicare patients. Medicare paid $303,570 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 263 Medicare patients who saw Dr. Lloyd in 2024. The largest group is 65 to 74, with 119 patients. 75% of them have cancer, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lloyd's median patient age at 71, with 51% women.

In 2024, Dr. Lloyd wrote 133 Medicare Part D claims for 61 patients. 87% of them were for generic drugs. CMS names the drug for 33 of them, across 1 drug with 11 or more claims each, at $283 in total drug cost. In 2023, CMS named 39 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Lloyd for performance year 2024, reported individually. Dr. Lloyd accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lloyd as offering telehealth.

Dmand AI links 20 papers to Dr. Lloyd, published from 2017 to 2025. 2023 was the busiest year, with 2. The most frequent topics are Intraoperative Care, Breast Neoplasms and Radiotherapy. Dr. Lloyd has published most often in Ann Surg Oncol. Dr. Lloyd's most frequent co-authors are Shane Lloyd, MD, Brian S. Kim, MD and Kevin Lin, MD.

CMS Open Payments shows 1 general payment to Dr. Lloyd from 1 drug or device company in 2022. Food and beverage make up the largest share, 100% of the total. Viewray Technologies Inc paid the most, $16.

Dr. Lloyd graduated from Penn State College of Medicine in 2015.

Dr. Lloyd is in network with 14 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.